Servier's Valdoxan receives EU approval for depression
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing approval to Servier's Valdoxan (agomelatine) for the treatment of major depressive episodes in adults. It is the first melatonergic antidepressant to be developed. The approval follows a recommendation from the EU's CHMP in November (www.scripnews.com, November 25th, 2008). The company said that it is finalising pricing or individual country launch dates. However, it is aiming to launch in the UK this summer.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.